Congenital cytomegalovirus infection

Semin Perinatol. 2018 Apr;42(3):149-154. doi: 10.1053/j.semperi.2018.02.002. Epub 2018 Mar 2.

Abstract

Each year, thousands of children are born with or develop permanent disabilities such as hearing loss, vision loss, motor and cognitive deficits from congenital CMV infection (cCMV). However, awareness of cCMV and its associated sequelae is very low in pregnant women and healthcare providers. Both targeted and universal approaches to screen newborns for CMV infection are now achievable due to recent scientific advances including the development of a rapid, high-throughput method for detecting CMV in saliva, the efficacy of antiviral treatment in symptomatic infants, and the demonstration of cost effectiveness of CMV screening. Future studies are needed to address gaps in our understanding on the role of non-primary maternal CMV infections, the evaluation of antiviral treatment in asymptomatic infants, and the implementation of prevention strategies for cCMV.

Keywords: Congenital cytomegalovirus infections; Maternal immunity; Newborn screening; Prevention; Sensorineural hearing loss.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cognitive Dysfunction / etiology
  • Cost-Benefit Analysis
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / congenital*
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / drug therapy
  • Female
  • Hearing Loss, Sensorineural / etiology
  • Humans
  • Infant, Newborn
  • Mass Screening
  • Neonatal Screening
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • Saliva
  • Vision Disorders / etiology

Substances

  • Antiviral Agents